Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    debio 0123

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05109975
Recruitment Status : Recruiting
First Posted : November 5, 2021
Last Update Posted : May 2, 2022
Sponsor:
Information provided by (Responsible Party):
Debiopharm International SA

Brief Summary:

This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of Debio 0123 as monotherapy with repeated dosing in adults with advanced solid tumors that recurred or progressed after prior therapy and/or for whom no standard therapy of proven benefit is available.

The purpose in Part 2, Expansion Part of this study, is to characterize the safety and tolerability of Debio 0123 when administered as monotherapy at the RP2D determined during the Dose Escalation Part 1 and to evaluate the preliminary anti-tumor activity of Debio 0123 when administered as monotherapy in participants with specific solid tumor types that recurred or progressed following prior lines of therapy.


Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: Debio 0123 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity
Actual Study Start Date : November 5, 2021
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : December 1, 2025

Arm Intervention/treatment
Experimental: Part 1: Dose Escalation
Participants will receive Debio 0123 orally in escalating dose cohorts during each 21-day treatment cycle until progression of disease, unacceptable toxicity, participant's withdrawal, or Investigator's decision, whichever occurs first.
Drug: Debio 0123
Debio 0123 orally during 21-day treatment cycles.

Experimental: Part 2: Expansion
Debio 0123 at the RP2D established in Part 1.
Drug: Debio 0123
Debio 0123 orally during 21-day treatment cycles.




Primary Outcome Measures :
  1. Part 1: Maximum Tolerated Dose (MTD) as Determined by Percentage of Participants with Dose Limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (each cycle is 21 days) ]
  2. Part 1: Recommended Phase 2 Dose (RP2D) as Determined by Percentage of Participants with DLTs and Cumulative Safety [ Time Frame: Cycle 1 (each cycle is 21 days) ]
  3. Part 2: Percentage of Participants with Serious Adverse Events (SAEs) [ Time Frame: Up to 30 days after the last dose of study treatment (up to 13 months) ]
  4. Part 2: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) and Laboratory Abnormalities [ Time Frame: Up to 30 days after the last dose of study treatment (up to 13 months) ]
  5. Part 2: Percentage of Participants with Treatment Discontinuations and Treatment Modifications due to Adverse Events (AEs) and Laboratory Abnormalities [ Time Frame: Up to end of study treatment (up to 12 months) ]
  6. Part 2: Overall Response Rate (ORR) [ Time Frame: From the start of study treatment until disease progression (up to 12 months) ]

Secondary Outcome Measures :
  1. Part 1: Percentage of Participants with SAEs [ Time Frame: Up to 30 days after the last dose of study treatment (up to 13 months) ]
  2. Part 1: Percentage of Participants with TEAEs and Laboratory Abnormalities [ Time Frame: Up to 30 days after the last dose of study treatment (up to 13 months) ]
  3. Part 1: Plasma Concentration of Debio 0123 [ Time Frame: Pre-dose and at multiple time points up to 8 hours (h) on Day 1, Cycle 1 (each cycle is 21 days) ]
    The pharmacokinetics (PK) of Debio-0123 will be evaluated in plasma.

  4. Parts 1 and 2: Anti-Tumor Activity as Assessed by Percentage of Participants with Tumor Response [ Time Frame: Parts 1 and 2: Up to 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Part 1 dose escalation only

    • Histologically or cytologically confirmed locally advanced or metastatic solid tumors.
    • Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
    • Disease progression under or following standard therapy and/or no available standard therapy of proven benefit.
  • Part 2 expansion only

    o Measurable disease per RECIST version 1.1 criteria

  • Part 1 dose escalation and Part 2 expansion

    • Accessible tumor for biopsy, and participant willing to undergo tumor biopsy unless archived tumor sample is available.
    • Eastern Cooperative Oncology Group (ECOG) performance status (PS) PS 0-1.
    • Life expectancy of at least 3 months, in the best judgment of the Investigator.
    • Adequate bone marrow, liver biochemistry, renal function, and coagulation status.
    • Willing to practice highly effective methods of contraception.

Exclusion Criteria:

  • Participants with active second malignancies requiring therapy in the last 6 months, with the exception of superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated surgically.
  • Current use of an investigational agent or a medical device.
  • Major surgery ≤4 weeks prior to the first dose of study treatment or who have not recovered from the surgical procedure.
  • Brain tumors and/or brain metastases unless they are asymptomatic, stable on recent imaging (not dated more than 28 days from the inclusion date), and have not required active treatment in the last month before study entry.
  • History of myocardial infarction or stroke within 6 months, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, family history of sudden death from cardiac-related causes, or any cardiotoxicity experienced after previous chemotherapy.
  • Known infection requiring systemic use of an antibiotic or antiviral agent.
  • Immunization with live or live-attenuated vaccine within 28 days prior to study inclusion or planned injection of live or live-attenuated vaccines.
  • Pregnancy or breast-feeding.
  • Inability or unwillingness to swallow oral medication.
  • Clinically significant gastrointestinal abnormality that would affect the absorption of the drug.
  • Chemotherapy, monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to starting study treatment. Palliative radiation for pain relief is allowed up to 1 week prior to starting study treatment.
  • Unresolved AEs or toxicities due to previous treatments, i.e., >Grade 1 or >Grade 2 for alopecia and endocrinopathies controlled by replacement therapy (example, hypothyroidism due to immune checkpoint inhibitors)

[Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.]


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05109975


Contacts
Layout table for location contacts
Contact: Debiopharm International S.A +41 21 321 01 11 clinicaltrials@debiopharm.com

Locations
Layout table for location information
United States, Arizona
HonorHealth Not yet recruiting
Scottsdale, Arizona, United States, 85258
United States, Michigan
South Texas Accelerated Research Therapeutics (START) Midwest Recruiting
Grand Rapids, Michigan, United States, 49546
United States, Texas
South Texas Accelerated Research Therapeutics (START) Recruiting
San Antonio, Texas, United States, 78229
Switzerland
Istituto Oncologico della Svizzera italiana - Ente Ospedaliero Cantonale Recruiting
Bellinzona, Switzerland, 6500
Universitätsspital Zürich, Dermatologische Klinik Recruiting
Zürich, Switzerland, 8058
Sponsors and Collaborators
Debiopharm International SA
Layout table for additonal information
Responsible Party: Debiopharm International SA
ClinicalTrials.gov Identifier: NCT05109975    
Other Study ID Numbers: Debio 0123-102
First Posted: November 5, 2021    Key Record Dates
Last Update Posted: May 2, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Debiopharm International SA:
Advanced Solid Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms